BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

Half a dozen regenerative therapies for hearing loss are in the clinic. 2020 should produce efficacy readouts with lessons about the mechanisms at play. While the late-stage programs for hearing loss are designed to protect...
BioCentury | Feb 15, 2020
Product Development

The Phase III trials and pharma sales most likely to be disrupted by COVID-19

The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth. In an analysis of MNC revenues and dependence on trial sites in China,...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

With its next-gen oncolytic virus, Astellas is reinforcing the promise of improved efficacy for versions that make cytokines stimulating T cells as well as innate immune cells. After more than two decades in development with...
BC Extra | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its...
BC Extra | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BC Extra | Jan 14, 2020
Company News

Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer. The announcement follows a 200% gain for Adaptimmune Therapeutics plc...
BC Extra | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds  HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...
BC Extra | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors. It believes that together,...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
Items per page:
1 - 10 of 2554
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

Half a dozen regenerative therapies for hearing loss are in the clinic. 2020 should produce efficacy readouts with lessons about the mechanisms at play. While the late-stage programs for hearing loss are designed to protect...
BioCentury | Feb 15, 2020
Product Development

The Phase III trials and pharma sales most likely to be disrupted by COVID-19

The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth. In an analysis of MNC revenues and dependence on trial sites in China,...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

With its next-gen oncolytic virus, Astellas is reinforcing the promise of improved efficacy for versions that make cytokines stimulating T cells as well as innate immune cells. After more than two decades in development with...
BC Extra | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its...
BC Extra | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BC Extra | Jan 14, 2020
Company News

Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer. The announcement follows a 200% gain for Adaptimmune Therapeutics plc...
BC Extra | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds  HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...
BC Extra | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors. It believes that together,...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
Items per page:
1 - 10 of 2554